This Viewpoint discusses the drug development portfolio—a family of trials assessing a drug for different indications or in different combinations with other drugs—and summarizes some of the challenges drug portfolios pose for policy, care, and human protections.
This case series involving children and young adults with cancer whose genomic sequencing results were the basis for clinical case recommendations charaterizes the number of clinically actionable findings and resulting patient outcomes.
With the first Everolimus for Liver Cancer Evaluation (EVOLVE-1) study, Zhu and coauthors investigated the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed. This randomized, double-blind, phase 3 study was conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function.
You currently have no searches saved.